# Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma

> **NCT05651828** · EARLY_PHASE1 · RECRUITING · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 34 (estimated)

## Conditions studied

- Advanced Basal Cell Carcinoma

## Interventions

- **DRUG:** Vismodegib 150 MG Oral Capsule

## Key facts

- **NCT ID:** NCT05651828
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-23
- **Primary completion:** 2028-12
- **Final completion:** 2029-12
- **Target enrollment:** 34 (ESTIMATED)
- **Last updated:** 2026-04-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05651828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05651828, "Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05651828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*